Information Provided By: 
Fly News Breaks for August 12, 2019
OSMT
Aug 12, 2019 | 08:56 EDT
With a "very low" $170M market capitalization, Osmotica Pharmaceuticals shares are discounting nearly all of the prospects for its two late-stage pipeline candidates - Ontinua ER and RVL-1201, potentially the first ever FDA approved non-surgical therapy for blepharoptosis, Jefferies analyst David Steinberg tells investors in a research note. The analyst lowered his price target for the shares to $10 from $13 and keeps a Buy rating on the name.
News For OSMT From the Last 2 Days
There are no results for your query OSMT
